With increasing FDA clearances for standalone software in sleep medicine, "software as a medical device" is becoming a key term. Experts explain what SaMD entails and explore its unique advantages and challenges.
A paper details a health economic analysis of Somryst, including changes in healthcare resource use, associated costs, and insomnia severity.
Pear will use the financing to accelerate reimbursement coverage for its products, creating a market access pathway in the prescription digital therapeutics industry.
Read More
Pear Therapeutics’s Somryst, a prescription digital therapeutic for use in the treatment of patients with chronic insomnia, is now available for patient use.
Read More
The award recognizes the cognitive behavioral therapy for insomnia software for impacting patient care through innovation.
Read MoreThe digital nature of Somryst offers opportunities to probe the user experience at a granular level.
Read More